Rocket Pharmaceuticals Beheer
Beheer criteriumcontroles 2/4
De CEO Rocket Pharmaceuticals is Gaurav Shah, benoemd in Jan2018, heeft een ambtstermijn van 6.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.01M, bestaande uit 7.8% salaris en 92.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.22% van de aandelen van het bedrijf, ter waarde $ 15.71M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.2 jaar en 6.8 jaar.
Belangrijke informatie
Gaurav Shah
Algemeen directeur
US$8.0m
Totale compensatie
| Percentage CEO-salaris | 7.8% |
| Dienstverband CEO | 6.8yrs |
| Eigendom CEO | 1.2% |
| Management gemiddelde ambtstermijn | 3.2yrs |
| Gemiddelde ambtstermijn bestuur | 6.8yrs |
Recente managementupdates
Recent updates
Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?
Sep 23
Rocket Pharmaceuticals: 2 Gene Therapy Candidates Anticipating Near-Term Review
Sep 15Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix
Jun 28We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely
Jun 09Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)
Apr 05Rocket Pharmaceuticals' Promising Path In Gene Therapy
Mar 01Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth
Nov 07Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering
Oct 03Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate
Aug 25We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate
Jul 22Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs
Jul 08Rocket Pharma: Poised For Growth In The Rare Disease Space
Jun 30Rocket Pharmaceuticals: A Struggling Company With Long-Term Upside
Jan 30We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely
Nov 09Rocket Pharmaceuticals Stock Forecast: Can It Rebound To $50 Levels? A Resounding Yes
Oct 01Rocket earns Evercore nod after positive data for rare genetic disease
Dec 17Rocket Pharma +33.6% after positive early data in Danon disease Phase 1 trial
Dec 09Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$258m |
| Jun 30 2024 | n/a | n/a | -US$253m |
| Mar 31 2024 | n/a | n/a | -US$249m |
| Dec 31 2023 | US$8m | US$625k | -US$246m |
| Sep 30 2023 | n/a | n/a | -US$253m |
| Jun 30 2023 | n/a | n/a | -US$249m |
| Mar 31 2023 | n/a | n/a | -US$237m |
| Dec 31 2022 | US$7m | US$598k | -US$222m |
| Sep 30 2022 | n/a | n/a | -US$199m |
| Jun 30 2022 | n/a | n/a | -US$192m |
| Mar 31 2022 | n/a | n/a | -US$172m |
| Dec 31 2021 | US$8m | US$590k | -US$169m |
| Sep 30 2021 | n/a | n/a | -US$186m |
| Jun 30 2021 | n/a | n/a | -US$165m |
| Mar 31 2021 | n/a | n/a | -US$155m |
| Dec 31 2020 | US$7m | US$540k | -US$140m |
| Sep 30 2020 | n/a | n/a | -US$99m |
| Jun 30 2020 | n/a | n/a | -US$89m |
| Mar 31 2020 | n/a | n/a | -US$82m |
| Dec 31 2019 | US$4m | US$480k | -US$77m |
| Sep 30 2019 | n/a | n/a | -US$85m |
| Jun 30 2019 | n/a | n/a | -US$82m |
| Mar 31 2019 | n/a | n/a | -US$79m |
| Dec 31 2018 | US$6m | US$414k | -US$75m |
Compensatie versus markt: De totale vergoeding ($USD 8.01M ) Gaurav } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.42M ).
Compensatie versus inkomsten: De vergoeding van Gaurav is gestegen terwijl het bedrijf verliesgevend is.
CEO
Gaurav Shah (49 yo)
6.8yrs
Tenure
US$8,013,553
Compensatie
Dr. Gaurav D. Shah, M.D., has been an Independent Director at Talaris Therapeutics, Inc. since December 2020. He serves as the Chief Executive Officer and Director of Rocket Pharmaceuticals, Ltd since Janu...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 6.8yrs | US$8.01m | 1.22% $ 15.7m | |
| Head of R&D | 6.8yrs | US$4.85m | 0.44% $ 5.7m | |
| Chief Technical Officer | 2.3yrs | US$4.38m | 0.062% $ 799.0k | |
| Chief Medical & Gene Therapy Officer | 6.8yrs | US$3.16m | 0.11% $ 1.4m | |
| Chief Financial Officer | less than a year | geen gegevens | geen gegevens | |
| General Counsel | 3yrs | US$1.56m | 0.070% $ 896.9k | |
| Director of Corporate Communications | no data | geen gegevens | geen gegevens | |
| Chief People Officer | 3.2yrs | geen gegevens | geen gegevens | |
| Senior VP of Clinical Safety & Chief Regulatory Officer | 4.6yrs | geen gegevens | geen gegevens | |
| Chief Business Officer | no data | US$2.82m | 0% $ 0 | |
| Chief Commercial Operations & Revenue Officer | less than a year | geen gegevens | geen gegevens |
3.2yrs
Gemiddelde duur
49yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van RCKT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 6.8yrs | US$8.01m | 1.22% $ 15.7m | |
| Independent Director | 10.3yrs | US$399.99k | 0.13% $ 1.6m | |
| Independent Director | 6.8yrs | US$429.98k | 0% $ 0 | |
| Independent Director | 8.8yrs | US$427.49k | 0% $ 0 | |
| Independent Director | less than a year | geen gegevens | geen gegevens | |
| Chairman of the Board | 6.8yrs | US$409.99k | 0.059% $ 756.6k | |
| Independent Director | 6.8yrs | US$417.49k | 0.13% $ 1.6m | |
| Independent Non-Executive Director | 2.7yrs | US$399.99k | 0% $ 0 | |
| Independent Director | 4.6yrs | US$409.99k | 0% $ 0 | |
| Director | 6.8yrs | US$399.99k | 0.22% $ 2.8m | |
| Independent Non- Executive Director | less than a year | US$568.70k | geen gegevens |
6.8yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van RCKT wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).